Suppr超能文献

卵巢癌:疾病及其复发的预防、检测和治疗。分子机制与个性化医疗会议报告。

Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report.

机构信息

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

出版信息

Int J Gynecol Cancer. 2012 Oct;22(8):S45-57. doi: 10.1097/IGC.0b013e31826bd1f2.

Abstract

OBJECTIVE

To review the current understanding of the underlying molecular, biologic, and genetic mechanisms involved in ovarian cancer development and how these mechanisms can be targets for prevention, detection, and treatment of the disease and its recurrence.

METHODS

In May 2012, we convened a meeting of researchers, clinicians, and consumer advocates to review the state of current knowledge on molecular mechanisms and identify fruitful areas for further investigations.

RESULTS

The meeting consisted of 7 scientific sessions ranging from Epidemiology, Early Detection, and Biology to Therapeutics and Quality of Life. Sessions consisted of talks and panel discussions by international leaders in ovarian cancer research. A special career development session by the Congressionally Directed Medical Research Program Department of Defense Ovarian Cancer Academy as well as an oral abstract and poster session showcased promising new research by junior scientists.

CONCLUSIONS

Technological advances in the last decade have increased our knowledge of the molecular mechanisms involved in a host of biological activities related to ovarian cancer. Understanding the role these mechanisms play in cancer initiation and progression will help lead to the development of prevention and treatment modalities that can be personalized to each patient, thereby helping to overcome this highly fatal malignancy.

摘要

目的

综述卵巢癌发生过程中涉及的潜在分子、生物学和遗传学机制的现有认识,以及这些机制如何成为疾病及其复发的预防、检测和治疗的靶点。

方法

2012 年 5 月,我们召集了研究人员、临床医生和消费者权益倡导者举行会议,以审查有关分子机制的现有知识状况,并确定进一步研究的有成果领域。

结果

会议由流行病学、早期检测和生物学、治疗学和生活质量共 7 个科学会议组成。会议由卵巢癌研究领域的国际领导者进行演讲和小组讨论。国会定向医学研究计划国防部卵巢癌学院的特别职业发展会议以及口头摘要和海报会议展示了初级研究人员有前途的新研究。

结论

过去十年中技术的进步增加了我们对与卵巢癌相关的一系列生物学活动中涉及的分子机制的认识。了解这些机制在癌症发生和进展中的作用将有助于开发能够针对每个患者进行个性化的预防和治疗方法,从而有助于克服这种高度致命的恶性肿瘤。

相似文献

3
Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer.
Int J Gynecol Cancer. 2019 Aug;29(Suppl 2):s2-s6. doi: 10.1136/ijgc-2019-000454.
4
Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.
Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S20-S22. doi: 10.1097/IGC.0000000000001118.
6
Future directions in the management of epithelial ovarian cancer.
Future Oncol. 2008 Jun;4(3):403-11. doi: 10.2217/14796694.4.3.403.
7
Research Summaries: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S1. doi: 10.1097/IGC.0000000000001116.
8
Fifth International Conference on Ovarian Cancer: challenges and opportunities.
Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013.
9
Ovarian cancer and high-risk women-implications for prevention, screening, and early detection.
Gynecol Oncol. 2003 Oct;91(1):15-31. doi: 10.1016/s0090-8258(03)00254-3.
10
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.

引用本文的文献

1
Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.
Front Pharmacol. 2025 Jun 4;16:1566330. doi: 10.3389/fphar.2025.1566330. eCollection 2025.
5
The Role of the Plasminogen Activator Inhibitor 1 ( ) in Ovarian Cancer: Mechanisms and Therapeutic Implications.
Glob Med Genet. 2024 Oct 29;11(4):358-365. doi: 10.1055/s-0044-1791734. eCollection 2024 Dec.
6
Parasites revive hope for cancer therapy.
Eur J Med Res. 2024 Oct 5;29(1):489. doi: 10.1186/s40001-024-02057-2.
7
Circular RNA circMAN1A2 promotes ovarian cancer progression through the microRNA-135a-3p/IL1RAP/TAK1 pathway.
PeerJ. 2024 Apr 24;12:e16967. doi: 10.7717/peerj.16967. eCollection 2024.
8
Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
PLoS One. 2024 Feb 1;19(2):e0298130. doi: 10.1371/journal.pone.0298130. eCollection 2024.
9
Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways.
Curr Med Chem. 2025;32(5):923-938. doi: 10.2174/0109298673276871231205043417.
10
hMOF induces cisplatin resistance of ovarian cancer by regulating the stability and expression of MDM2.
Cell Death Discov. 2023 Jun 8;9(1):179. doi: 10.1038/s41420-023-01478-y.

本文引用的文献

2
High-grade serous ovarian cancer arises from fallopian tube in a mouse model.
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921-6. doi: 10.1073/pnas.1117135109. Epub 2012 Feb 13.
3
Women's cancer survivorship: time to gear up!
Gynecol Oncol. 2012 Mar;124(3):377-8. doi: 10.1016/j.ygyno.2012.01.004.
4
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2358-63. doi: 10.1073/pnas.1120733109. Epub 2012 Jan 27.
6
Rethinking ovarian cancer: recommendations for improving outcomes.
Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
7
Patient-reported outcomes: clinical trials in ovarian cancer.
Int J Gynecol Cancer. 2011 May;21(4):782-7. doi: 10.1097/IGC.0b013e31821bb8be.
9
Global cancer statistics.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
10
The origin of ovarian carcinomas: a unifying hypothesis.
Int J Gynecol Pathol. 2011 Jan;30(1):12-21. doi: 10.1097/PGP.0b013e3181f45f3e.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验